Design issues of randomized phase II trials and a proposal for phase II screening trials.
about
Gabapentin for smoking cessationFound in translation: Integrating laboratory and clinical oncology researchSuggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialCurrent issues in oncology drug development, with a focus on Phase II trialsIrinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.Randomized phase II clinical trials.The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.Effective incorporation of biomarkers into phase II trialsPatient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Randomized phase II trials: time for a new era in clinical trial designShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancerA prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trialEarly-stage squamous cell carcinoma of the oropharynx: radiotherapy vs. trans-oral robotic surgery (ORATOR)--study protocol for a randomized phase II trial.Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Outcome--adaptive randomization: is it useful?Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemiaA Bayesian approach for unplanned sample sizes in phase II cancer clinical trialsUnique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer.The direct assignment option as a modular design component: an example for the setting of two predefined subgroupsRemaining challenges in childhood cancer and newer targeted therapeutics.A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States.Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trialSurveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialTumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741Blood and marrow transplant clinical trials network state of the Science Symposium 2014Significant mobilization of both conventional and regulatory T cells with AMD3100.The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studiesDesign issues in randomized phase II/III trials.Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remissionDrug development in oncology: classical cytotoxics and molecularly targeted agents.Phase II cancer clinical trials with heterogeneous patient populations.Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancerEvaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncologyMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma
P2860
Q24645235-AC7921B2-3F23-4533-9A79-87B923A353ADQ28744471-4A52E296-E950-4E50-A498-D160CE8E89D5Q30437854-AF6C69FC-E6B4-4778-AF92-472102F1A8DBQ31075401-5563E0E8-604B-482A-993C-E136CEE1765CQ33420821-9EE5CD7E-C59C-4E2D-8F6D-B2C63072AA08Q33429827-E3529308-5BAF-49EC-A8DE-1B0BA3C12A11Q33433456-986BA6F0-F628-4648-862B-ED4A775B0D79Q33442162-B1067DC6-3742-4BF9-AC03-531B3CF8A78EQ33624082-B9FCC1BE-FA28-4B21-A873-AF2FAE57A21AQ33732581-22F8CFBE-E5AC-4B6B-989B-692E8C2C1313Q33813448-F5C3731B-60F6-41AF-8059-A7CE02D9E69EQ33870594-30D1B381-8A3A-4A25-8D3D-CE98B9D79435Q33942485-FD412F4A-2CFE-4DB5-A8E0-7907C595D31DQ34040130-5AA6CFA0-C551-4763-A4F3-05789AFB4D19Q34137050-24E1173A-2942-4CDD-A5B2-DB29CA51CC0CQ34193514-EF32916F-974D-4BBA-8394-8475A9E5D02DQ34360263-11333028-ECF4-4889-9AB4-D3266EDE5F75Q34580450-8846399C-0FB4-443E-92CB-F298E85CF607Q34628493-893CCC55-A071-4B62-87A2-43124F44E69CQ34633455-9643A9F6-C585-4455-9B8D-E1A9BE5803ADQ34667846-06907872-DA1A-46F7-B307-8F1075B9B0B7Q34790388-9199DFFB-72EB-4393-9E85-BF09E4FD8462Q34815765-78B7869A-C5CB-4AC5-A29B-8FFBB413A025Q34820332-1E66723F-A8A9-49D9-9799-208481021A9AQ35026541-291A47B3-153E-4C36-AC40-DCB9A8E549C1Q35106844-968C12EE-990A-40C4-B730-4E7FF5B1B278Q35200080-BD98F2EA-C878-4432-8F88-4997BFB6437DQ35206566-8A025427-3E07-48DE-9926-51E43DB7751CQ35253783-97E8FFD9-0DFD-4233-9FBA-3189F8BDC720Q35584926-ED2266B7-DC89-4441-BD8E-2A4CBA3FA294Q35591760-2BD62560-7682-4790-8BCC-5BA4A4324314Q35623657-A384B0A4-86DE-4D8E-B853-E9CCD048F1EDQ35693300-FF0EC2EB-5CBA-4F86-BA37-EA849DB50663Q35808427-50553B74-CB03-42FA-8471-03FDCBAC830AQ35811811-B0A6A3A9-954F-4019-A068-FD80AC6AE3C9Q35827606-C5B35877-F77F-451A-BAAC-49AF384F94D9Q35882757-708DD46B-6D00-444C-B02A-DFAC9A52DCE0Q35987082-3C456147-A57F-4621-B029-9CE358D4CF0BQ36036648-5392158A-4E6C-4D8F-87E6-234973379053Q36097706-CC5980BA-18B7-4CE0-A3FA-DB2856BC5782
P2860
Design issues of randomized phase II trials and a proposal for phase II screening trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Design issues of randomized phase II trials and a proposal for phase II screening trials.
@en
type
label
Design issues of randomized phase II trials and a proposal for phase II screening trials.
@en
prefLabel
Design issues of randomized phase II trials and a proposal for phase II screening trials.
@en
P2093
P356
P1476
Design issues of randomized phase II trials and a proposal for phase II screening trials.
@en
P2093
Edward L Korn
Lawrence V Rubinstein
Malcolm A Smith
S Percy Ivy
Sally Hunsberger
P304
P356
10.1200/JCO.2005.01.149
P407
P577
2005-10-01T00:00:00Z